EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports

Weiqiang Song, Jiankun Zhang, Guangpeng Chen, Yunzhao Ji

Frontiers in Public Health · 06.07.2026 · 14

DOI: 10.3389/fpubh.2026.1882548 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Frontiers in Public Health, online erschienen am 06.07.2026. Verfasst von Weiqiang Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hebei Petrochina Central Hospital, Langfang, Hebei, China. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A growing share of oncology drugs receive FDA approval via expedited pathways based on interim RCT analyses, leaving safety data relatively immature at approval. Whether the relative toxicity of approved therapeutics shifts as trials mature remains unquantified.

Methods

Phase II–III RCTs underpinning FDA oncology approvals from 2006 to 2025 were eligible if both the approval-stage dataset and at least one subsequent publication reported grade ≥3 AEs or serious AEs (SAEs). For each trial, experimental-versus-control odds ratios (ORs) were computed at both timepoints, with within-trial change indexed by the ratio of odds ratios (ROR), defined as the updated OR divided by the initial OR (ROR > 1 indicating greater experimental-arm toxicity after maturation). Random-effects meta-analyses pooled log-scale estimates; meta-regression explored effect modifiers and sources of heterogeneity.

Results

Ninety-nine RCTs met eligibility and, after splitting seven three-arm trials, yielded 106 pairwise comparisons (103 for grade ≥3 AEs; 70 for SAEs). Pooled OR for grade ≥3 AEs rose from 1.09 (95% CI, 0.93–1.22) to 1.29 (1.03–1.43); meta-analytic ROR showed a statistically significant increase at 1.095 (1.038–1.156; p = 0.001; I 2 = 12.8%), with 78/103 comparisons shifting toward greater experimental toxicity. For SAEs, pooled OR rose from 1.32 (1.21–1.42) to 1.45 (1.27–1.59); ROR was 1.06 (0.97–1.17; p = 0.22; I 2 = 46.8%), directionally concordant but not statistically significant, with upward shifts in 49/70 comparisons. Amplification was most evident for all-cause events and in crossover-permitted, blinded, medium-sized, and later-line trials, and in lung, prostate, and breast cancer. RORs declined across more recent cohorts ( β = −0.027, p = 0.009 for SAEs); larger enrollment, longer follow-up, blinded designs, and all-cause ascertainment predicted greater drift, while mature initial follow-up and metastatic settings attenuated it. We derived an exploratory Toxicity Drift Predictor to estimate post-approval ROR of SAEs from pre-approval trial features.

Conclusion

FDA-approved oncology therapeutics show systematic post-approval increases in relative toxicity, most pronounced for all-cause events and designs prolonging differential exposure. Though attenuated for recent agents, the approval-stage safety profile represents a lower-bound estimate of long-term comparative harm, supporting evidence-maturity–based dynamic oversight with predefined safety-update milestones and structured surveillance of delayed toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsNeoplasmsUnited StatesHumansUnited States Food and Drug AdministrationRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

FDA approvaladverse eventscomparative toxicityevidence maturityoncology drugspost-marketing surveillance

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Hebei Petrochina Central Hospital, Langfang, Hebei, China.
  • School of Public Health, Fudan University, Shanghai, China.
  • Department of Anesthesiology, Hebei Petrochina Central Hospital, Langfang, Hebei, China.

Zitieren

APA

Song, W., Zhang, J., Chen, G., & Ji, Y. (2026). Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1882548

Vancouver

Song W, Zhang J, Chen G, Ji Y. Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1882548

BibTeX
@article{Song2026,
  author = {Song, Weiqiang and Zhang, Jiankun and Chen, Guangpeng and Ji, Yunzhao},
  title = {Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports},
  journal = {Frontiers in Public Health},
  year = {2026},
  volume = {14},
  doi = {10.3389/fpubh.2026.1882548}
}
Kostenlos starten →